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Abstract
Background: Hypovitaminosis D may be related to some metabolic vulnerable, including metabolic disorders associated with in-
flammatory cytokines and insulin resistance in subjects undergoing methadone maintenance treatment (MMT).
Objectives: This study aimed to determine the impact of vitamin D intake on withdrawal symptoms and genetic response related
to inflammatory cytokines and insulin in patients treated with MMT.
Methods: This investigation was performed on 40 subjects under MMT to consume either 50,000 IU vitamin D supplements (n = 20)
or placebo (n = 20) every 2 weeks for 12 weeks, between April and June 2017 in Kashan, Iran. The clinical opiate withdrawal symptoms
(COWS) were evaluated to examine withdrawal scale and gene expression at baseline and after the a 3-month intervention. Statistical
analysis of the data was performed using SPSS 18 with Fisher’s exact test, t-test, chi-square, and ANCOVA. Also, P values < 0.05 were
considered statistically significant.
Results: The results of our study showed that compared with the placebo, taking vitamin D downregulated interleukin-1 (IL-1) ex-
pression (P = 0.01) in peripheral blood mononuclear cells (PBMCs) of patients under MMT. In addition, consuming vitamin D in-
creased peroxisome proliferator-activated receptor gamma (PPAR-γ) expression (P = 0.01). Administration of vitamin D did not
change COWS and IL-8 and tumor necrosis factor-alpha (TNF-α) expression.
Conclusions: According to the results of the present study, vitamin D can be recommended as an adjunct to MMT which may elevate
the quality of life and decrease methadone side effects.
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1. Background
Methadone maintenance therapy (MMT) is favorable
for the treatment of opioid dependence (1). In Iran, the
prevalence of opioid use is rising and was nearly three
times higher than the prevalence worldwide. About 1.2 mil-
lion Iranians have opioid dependency (2). About 500,000
people are under buprenorphine and methadone ther-
apy (3). Drug abuse (i.e., opioids and methadone) can
increase inflammatory parameters and oxidative stress
(4). In vitro and in vivo medical evidence has reported
that opioid dependence has complication immunomodu-
latory impacts on adaptive immune responses (5) and in-
flammatory markers (6). Increased gene expression of in-
flammatory cytokines has been evaluated in noradrener-
gic locus coeruleus cells in the brains of opioid-dependent
patients (7). In addition, it was reported that individuals
with heroin dependence encounter energy reduction, car-
bohydrate and protein consumption, and elevation in fatty
acids intakes for four-year MMT (8).
Recently, the issue of vitamin D administration is sug-
gested in patients under MMT. This may be due to the fa-
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vorable effects of vitamin D in subjects under MMT and
diseases associated with metabolic disorders. Previous
studies demonstrated that prescription of a pharmaco-
logic dose of vitamin D (50,000 IU/2-week) for 3 months
in subjects under MMT improved mental health scales and
metabolic outcomes (9). Whether such improvements
in biochemical variables would translate into clinically
meaningful reductions in the harmful sequelae of patients
under MMT remains unknown. Regarding the effects
of vitamin D administration on inflammatory cytokines,
a study of colorectal cancer subjects demonstrated re-
duced circulating levels of inflammatory markers after
vitamin D intake (10). In subjects under hemodialysis,
supplementation with vitamin D significantly decreased
inflammatory factors (11); however, the inflammatory cy-
tokines could not be ameliorated in non-diabetic popula-
tion (12). In a study related to the effect of vitamin D on
peroxisome proliferator-activated receptor gamma (PPAR-
γ), high-dose vitamin D for 2 months significantly elevated
PPAR-γ gene expression (13). In another study, vitamin D
deficiency led to the dysregulation of glycemic control in
Goto-Kakizaki rats by decreasing gene expression of PPAR-
γ (14).
Vitamin D may result in improving mental health
symptoms, metabolic profiles, biomarkers of oxidative
stress and inflammation through their effect on central
nervous system, neuronal circuits and the regulation of
pro-inflammatory cytokines in cellular systems (9, 10, 15),
as well as affecting signaling pathways and gene expres-
sion (16). In addition, vitamin D-treated animals, which
consumed methamphetamine demonstrated that the oral
taking of vitamin D can decrease metabolites and pro-
tection of dopaminergic system against dopamine and
serotonin depleting (17). Although the impacts of con-
sumption of vitamin D on psychological outcomes have
attracted a great deal of attention, data on the gene ex-
pression related to inflammatory cytokines and insulin
metabolism in subjects under MMT are limited and con-
tradictory. The current study, therefore, aimed to evaluate
the effects of colecalciferol intake on gene expression in-
volved inflammatory cytokines and insulin metabolism in
patients under MMT.
2. Objectives
Owing to the importance of vitamin D, this study
aimed at examining vitamin D supplementation on with-




This study was registered in the Iranian website for
registration of clinical trials as http://www.irct.ir, no:
IRCT2017042433551N1, in accordance with the Declaration
of Helsinki guideline. In addition, written informed con-
sent was taken from all participants. Ethical approval code
was IR.Kaums.REC.1395.114 for this study. This investigation
was conducted on 40 patients undergoing MMT who re-
ferred to the Golabchi Clinic in Kashan, Iran. The included
subjects were aged 18 - 60 years, currently undergoing MMT
and opioid dependence in the past year. Exclusion crite-
ria were using colecalciferol 3 months before the interven-
tion, and people with a history of metabolic diseases, in-
cluding diabetes, cardiovascular and hypertension before
the intervention, and unwillingness to contribute during
the intervention.
3.2. Study Design
At baseline, male patients were randomly divided into
two groups to receive either 50,000 IU vitamin D (Zahravi
Pharmaceutical Company, Tabriz, Iran) or placebo (Barij
Essence, Kashan, Iran) (n = 20 each arm) every 2 weeks for
12 weeks. Randomization was performed using computer-
generated random numbers. The lack of information
about the suitable vitamin D dosage for subjects with MMT
made us use the above-considered dose of vitamin D based
on a previous report in chronic liver disorder cases (18).
Methadone was administered as syrup for the subjects.
Compliance with the colecalciferol and placebo intake was
done by the quantification of 25 (OH) vitamin D values.
3.3. Clinical Assessment
The clinical opiate withdrawal scale (COWS), as a reli-
able and valid measure for evaluating withdrawal signs,
was assessed to examine withdrawal symptoms at base-
line and after a 3-month intervention (19). Nazari et al.
(20), approved the validity and reliability of Persian ver-
sion of COWS among Iranian population with an opiate
withdrawal syndrome. In the above-mentioned question-
naire, Cronbach’s alpha coefficients ranged from 0.66 to
0.88, while validity and reliability coefficients were 0.73
and 0.88, respectively.
3.4. Assessment of Outcomes
Interleukin-1 (IL-1), IL-8, and tumor necrosis factor
alpha (TNF-α) expression as the primary outcome and
PPAR-γ expression and withdrawal symptoms were
considered the secondary outcomes. Furthermore, 25-
hydroxyvitamin D values were evaluated using an ELISA
kit (IDS, Boldon, UK).
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3.5. Isolation of Lymphocyte Cells
Fasting samples (10 mL) were collected in Kashan Ref-
erence Laboratory at both baseline and endpoint of the in-
tervention. Samples were taken for cell count and viabil-
ity testing using trypan blue, as well as RNA and DNA ex-
traction (21). Each sample’s OD 260/280 ratio ranged from
1.7 to 2.1, which showed no contamination with both pro-
tein and DNA (21). Gene expression of IL-1, IL-8, TNF-α, and
PPAR-γ was assessed by quantitative RT-PCR, using Light-
Cycler technology (Roche Diagnostics, Rotkreuz, Switzer-
land) with SYBR green detection and Amplicon Kit (Table
1).


































Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IL-1,
interleukin-1; IL-8, interleukin-8; PPAR-γ , peroxisome proliferator-activated
receptor gamma; TNF-α, tumor necrosis factor alpha.
3.6. Sample Size
In this study, we used a randomized clinical trial sam-
ple size calculation formula using power analysis software,
where type one (α) and type two errors (β) were 0.05 and
0.20 (power = 80%), respectively. According to our previ-
ously published trial (16), we used 0.15 fold changes as the
SD and 0.15 fold changes as the change in mean (d) of TNF-
α as a primary outcome. Based on the formula, we needed
16 patients in each group. After allowing for 20% dropouts
in each group, the final sample size was 20 persons in each
group.
3.7. Statistical Analysis
The normality of data distribution was assessed us-
ing Kolmogorov-Smirnov test. Independent sample t-test
was applied to determine the differences in anthropomet-
ric measures and dietary intakes between the two inter-
vention groups. Ratios differences were evaluated using
Fisher’s exact test. To determine the effects of vitamin D
administration on gene expression influenced by inflam-
mation and insulin, we used independent sample t-test.
P values < 0.05 were considered statistically significant.
All statistical analyses performed using the Statistical Pack-
age for Social Science version 18 (SPSS Inc., Chicago, Illinois,
USA).
4. Results
Twenty patients in both groups completed the trial out
of 45 patients who were recruited in our study (5 patients
were excluded from the study because of not meeting the
inclusion criteria). On average, higher than 90% of cap-
sules were taken in both groups. No serious adverse ef-
fects were reported following the taking of vitamin D in pa-
tients.
Mean age, height, weight, body mass index (BMI) and
COWS at baseline and end-of-trial, age of first use, route
of use of illegal opioid, type of drug, methadone dose, du-
ration of MMT, psychiatric comorbidity and use of other
drugs were not significantly different between the two
groups (Table 2). After the 12-week intervention, serum
25(OH) vitamin D levels significantly increased in the in-
tervention group compared with the placebo group (+8.5
± 5.1 vs. -0.8 ± 3.0, P < 0.001).
Considering the 3-day dietary records obtained dur-
ing the intervention, there was no statistically significant
difference in terms of dietary macro- and micro-nutrient
intakes between vitamin D and placebo groups (data not
shown).
Results of RT-PCR demonstrated that compared with
the placebo, vitamin D supplementation down-regulated
gene expression of IL-1 (P = 0.01) in PBMCs of patients un-
der MMT (Figure 1). There was no significant effect of vi-
tamin D supplementation on gene expression of IL-8 and
TNF-α in PBMCs of patients under MMT (Figures 1 and 2).
Also, compared with the placebo, vitamin D supplementa-
tion up-regulated gene expression of PPAR-γ (P = 0.01) in
PBMCs of patients under MMT (Figure 2). We adjusted the
analysis for age and BMI at baseline. When we adjusted the
analysis for age and baseline BMI, our findings did not al-
ter (Table 3). In addition, when we controlled the analysis
for age, BMI at baseline, duration of MMT and psychiatric
comorbidity, our findings did not alter.
5. Discussion
We assessed the favorable effects of vitamin D intake
for 3 months on withdrawal symptoms and gene expres-
sion associated with inflammatory cytokines and insulin
Iran J Psychiatry Behav Sci. In Press(In Press):e86969. 3
Uncorrected Proof


































































Figure 2. Effect of a 3-month supplementation with vitamin D or placebo on expression ratio of TNF-α and PPAR-γ gene in PBMCs of patients under MMT.
subjects under MMT. This study documented that vitamin
D administration for 3 months among MMT subjects, com-
pared with the placebo, ameliorated IL-1 and PPAR-γ ex-
pression, but did not impact IL-8 and TNF-α expression and
COWS. This is the first investigation reporting the effects
of vitamin D administration on withdrawal symptoms and
gene expression related to metabolic outcomes among pa-
tients under MMT. It must be kept in mind that a number of
studies have shown that patients treated with methadone
experience withdrawal symptoms that the onset of with-
drawal syndrome lasts from 7 to 10 days and these symp-
toms continue up to few weeks (22). The most common rea-
son for successful termination of MMT treatment was the
belief that they needed the higher methadone dose and
has experiences the withdrawal symptoms. Although we
believe that these symptoms are not common in long-term
periods; further studies are needed to confirm our find-
ings.
Of note, MMT leads to some disorders, including in-
creased inflammatory cytokines (4). A number of studies
have documented that hypovitaminosis D and BMD are dif-
ficulties in patients under MMT (9, 23). In a study of sub-
jects with chronic pain, 93% of them had colecalciferol defi-
ciency (24). Authors documented that vitamin D intake for
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Table 3. Adjusted Changes in Gene Expression Related to Inflammation, Insulin and
Lipid in Maintenance Methadone Treatment Patients That Received Either Vitamin
D Supplements or Placebo (N = 20)a
Placebo Group Vitamin D Group Pb
IL-1 (fold change)
Model 1c -50.2 ± 23.4 78.3 ± 23.4 < 0.001
Model 2d -40.5 ± 23.3 68.7 ± 23.2 0.002
IL-8 (fold change)
Model 1c -37.3 ± 16.6 -6.9 ± 16.6 0.20
Model 2d -43.3 ± 19.3 -0.9 ± 19.3 0.13
TNF-α (fold change)
Model 1c 0.5 ± 0.2 -0.1 ± 0.2 0.05
Model 2d 0.5 ± 0.2 -0.1 ± 0.2 0.08
PPAR-γ (fold change)
Model 1c 0.5 ± 0.5 -2.1 ± 0.5 < 0.001
Model 2d 0.5 ± 0.5 -2.1 ± 0.5 < 0.001
Abbreviations: IL-1, interleukin-1; IL-8, interleukin-8; PPAR-γ , peroxisome
proliferator-activated receptor gamma; TNF-α tumor necrosis factor alpha.
aValues are expressed as mean ± SD.
bObtained from ANCOVA.
cModel 1: Adjusted based on age, BMI at baseline and baseline values of gene
expression of variables.
dModel 2: Adjusted based on age, BMI at baseline and baseline values of gene
expression of variables, type of drug, duration of MMT and psychiatric comor-
bidity.
3 months in MMT subjects could not improve withdrawal
symptoms. The effects of vitamin D intake on withdrawal
symptoms among subjects under MMT are limited. Sev-
eral studies have shown that hypovitaminosis D may be
important in addiction and may have an effect in desta-
bilizing serotoninergic, dopaminergic, and glutamatergic
pathways, which subsequently contribute to the degener-
ating mental state (25). In addition, vitamin D indirectly
interferes with neuron membrane integrity, as well as its
function, which may improve neuron malfunction (26).
We showed that consuming vitamin D for 3 months
downregulated IL-1 expression, but could not affect IL-8
and TNF-α expression. Previously, the effect of vitamin D
administration on inflammatory factors was evaluated in
patients without MMT. In agreement with our study, vita-
min D significantly reduced IL-1β expression in macrovas-
cular endothelial cells compared with non-treated cells
(27). The same findings were reported by other studies
(16, 28). However, a bolus dose of vitamin D (250,000
IU) in subjects with cystic fibrosis was related to a reduc-
tion in two inflammatory markers, IL-6 and TNF-α, but
did not affect IL-1 and IL-8 (29). Pro-inflammatory mark-
ers directly oppose opioid actions (4). In addition, another
study showed that pro-inflammatory markers, including
IL-1β and TNF-α were related to enhancing pain intensity
(30). Increased inflammatory variables may play an active
role in the progress of many metabolic disturbances, such
as type 2 diabetes mellitus or atherosclerosis progression
leading to cardiovascular diseases (31). Colecalciferol may
decrease inflammatory variables via regulation of nuclear
factor κB (NF-κB) and mitogen-activated protein (MAP) ki-
nase (32).
We found that vitamin D administration to patients
under MMT for 3 months upregulated PPAR-γ expres-
sion. Previously, impaired insulin metabolism was demon-
strated in MMT compared with control group (33). More-
over, circulating levels of leptin, adiponectin and resistin
significantly change in individuals with chronic heroin
addiction (34), which in turn would result in decreasing
insulin sensitivity. In accordance with these results, Ho-
seini et al. (13) observed that combined high-dose vita-
min D and aerobic exercise for 2 months significantly in-
creased PPAR-γ expression in the liver. Also, it was docu-
mented that hypovitaminosis D resulted in the dysregula-
tion of insulin sensitivity by reducing adipose PPAR-γ ex-
pression and deteriorating β-cell function (14). In addi-
tion, gene expression of PPAR-γ was upregulated by vita-
min D in tissue of pregnant rats, but its expression was
not significantly increased in the liver (35). However, this
finding differs from prior studies on pre-adipocytes, which
demonstrated that vitamin D considerably downregulated
the C/EBP-α and PPAR-γ expression (36). Overall, our re-
sults suggest that vitamin D modulate insulin and lipid
metabolism by blocking the expression of lipogenic en-
zymes in adipose tissue and the liver. The important role of
PPAR-γ in regulating motivated behaviors and emotional
control is documented with neuroanatomical data, show-
ing relatively high concentrations of receptor expression
in neurons of the caudate-putamen, septum, and hypotha-
lamus (37). A prior study demonstrated that the activa-
tion of the PPAR-γ led to inhibition of stress response in
rodents (38). Currently, effective drugs for addiction treat-
ment are methadone and buprenorphine. Therefore, ex-
isting evidence suggests that activating PPAR-γ may rep-
resent a promising effective treatment approach for drug
abuse (39).
5.1. Limitations
The present study had some limitations. Firstly, dura-
tion of this study was short. Long-term duration may lead
to better effects in withdrawal symptoms. Secondly, we did
not evaluate the effects of colecalciferol on cognitive func-
tion. Thirdly, we could not evaluate the acute and chronic
pain in patients under MMT.
5.2. Conclusions
Totally, taking vitamin D for 3 months in patients un-
der MMT significantly ameliorated the IL-1 and PPAR-γ ex-
pression, but did not affect IL-8 and TNF-α expression and
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COWS. Vitamin D can be recommended as an adjunct to
MMT in opioid withdrawal protocol which may elevate the
quality of life and may diminish methadone adverse ef-
fects.
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Table 2. General Characteristics of the Study Participants (N = 20)a
Placebo Group Vitamin D Group Pb
Age, y 43.4 ± 9.8 40.7 ± 6.4 0.30
Height, cm 172.7 ± 7.7 170.5 ± 8.7 0.40
Weight at study baseline, kg 77.1 ± 12.2 71.9 ± 11.4 0.17
Weight at end-of-trial, kg 77.0 ± 13.0 71.8 ± 11.8 0.19
Weight change, kg -0.1 ± 1.9 -0.1 ± 1.3 0.98
BMI at baseline, kg/m2 25.9 ± 3.8 24.8 ± 3.8 0.39
BMI at end-of-trial, kg/m2 25.8 ± 4.2 24.7 ± 3.9 0.41
BMI change, kg/m2 -0.1 ± 0.6 -0.1 ± 0.4 0.95
Vitamin D at baseline, ng/mL 13.8 ± 4.5 14.7 ± 3.7 0.49
Vitamin D at end-of-trial, ng/mL 13.0 ± 6.4 23.2 ± 7.0 < 0.001
Vitamin D change, ng/mL -0.8 ± 3.0 8.5 ± 5.1 < 0.001
Withdrawal symptoms at baseline 27.6 ± 7.5 24.1 ± 13.1 0.30
Withdrawal symptoms at end-of-trial 25.9 ± 7.9 21.4 ± 8.1 0.08
Withdrawal symptoms change -1.6 ± 4.3 -2.7 ± 9.7 0.67
Age of first use, y 22.8 ± 8.9 22.4 ± 8.8 0.88
Education, % 0.63c
Illiterate 10 (50) 8 (40)
Elementary 3 (15) 4 (20)
Intermediate 5 (25) 7 (35)
Diploma 2 (10) 1 (5)
Marital status, % 0.75c
Single 12 (60) 10 (50)
Married 4 (20) 3 (15)
Widow/divorced 4 (20) 7 (35)
Job, % 0.81c
Unemployed 13 (65) 9 (45)
Employed 0 (0) 1 (5)
Others 7 (35) 10 (50)
Route of use of illegal opioid, % 0.91c
Smoking 6 (30) 7 (35)
Smoking and injecting 5 (25) 4 (20)
Mix 9 (45) 9 (45)
Type of drug, % 0.88c
Poly-drug users 13 (65) 14 (70)
Opium and opium residues 4 (20) 4 (20)
Opium and heroin 3 (15) 2 (10)
Methadone dose, mL/d 18.5 ± 6.1 18.7 ± 6.8 0.90
Duration of MMT, y 6.6 ± 2.8 5.7 ± 2.0 0.24
Psychiatric comorbidity, % 0.88c
None 14 (70) 12 (60)
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Mood disorder 2 (10) 2 (10)
Anxiety disorder 2 (10) 2 (10)
Mood and anxiety disorders 1 (5) 3 (15)
Others disorders 1 (5) 1 (5)
Use of other drugs 1.00c
None 13 (65) 13 (65)
Benzodiazepine 7 (35) 7 (35)
aValues are expressed as mean ± SD or No. (%).
bObtained from independent t-test.
cObtained from Fisher’s exact test.
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